Back HCV Treatment

HCV Drug Development: Merck Acquires Idenix, FDA Lifts Sovaprevir Hold

Merck this week announced that it will purchase Idenix, a specialty biopharmaceutical company developing several hepatitis C virus (HCV) drug candidates. In related news, Achillion announced that the U.S. Food and Drug Administration (FDA) has lifted a clinical hold on one of its drugs and a clinical trial of another is now underway.

alt

Read more: